Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

aristo pharma gmbh - memantin hydrochlorid -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

aristo pharma gmbh - memantin hydrochlorid -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

tillomed pharma gmbh - tranexamsÄure -

Europäische Union - Deutsch - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostata-neoplasmen - endokrine therapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - olaparib - eierstock-neoplasmen - antineoplastische mittel - eierstock cancerlynparza ist angezeigt als monotherapie zur erhaltungstherapie von erwachsenen patienten mit fortgeschrittenem (figo-stadien iii und iv) brca1/2-mutierten (keimbahn und/oder somatisch) high-grade-epithelialen eierstockkrebs, eileiterkrebs oder primärem peritonealkarzinom, die in reaktion (vollständige oder teilweise) nach abschluss der first-line-chemotherapie auf platinbasis. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 und 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. sollten patienten, die zuvor behandelt wurden, mit einem anthrazyklin und einem taxan in der (neo)adjuvanten oder metastasierten setting, es sei denn, die patienten waren nicht geeignet für diese behandlung (siehe abschnitt 5. patienten mit hormon-rezeptor (hr)-positivem brustkrebs sollten auch fortgeschritten, die am oder nach vorheriger endokriner therapie, oder werden als ungeeignet für die endokrine therapie. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamid - prostata-neoplasmen - endokrine therapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gmbh - tadalafil -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gmbh - tadalafil -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

genericon pharma gmbh - tadalafil -

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biomo pharma gmbh - geschäftsanschrift - (3263852) - bicalutamid - filmtablette - teil 1 - filmtablette; bicalutamid (25764) 50 milligramm